相关实验视频

Updated: May 13, 2026

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

对流感A (H5N8) 亚型的疫苗菌株的构建和免疫战略优化

Shuxia Zhang¹, Jing Tang¹, Liqi Liu¹

¹National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

|April 26, 2025

概括

开发禽流感病毒 (AIV) 疫苗对于疫情准备至关重要. 这项研究优化了H5N8 AIV候选疫苗,发现MF59辅助剂和特定免疫策略有效地保护了小鼠.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
疫苗学疫苗学疫苗学

背景情况:

禽流感病毒 (AIV) 亚型,包括H5N1,H5N6和H5N8,在鸟类中传播,并导致人类感染.
疫苗开发对于减轻大流行性流感威胁至关重要.

研究的目的:

使用反向遗传学 (RG) 构建和评估H5N8 AIV的候选疫苗病毒 (CVV).
通过辅助剂选择和免疫策略改进,优化免疫性和对H5N8 AIV挑战的保护.

主要方法:

使用基于人类感染H5N8 AIV菌株的RG生成了候选疫苗病毒 (CVV).
在BALB/c小鼠中评估了免疫性,使用无活化rH5N8/PR8与,ISA51和MF59辅助剂.
优化了剂量,施用途径和免疫接种间隔.

主要成果:

最佳的免疫包括10μg的无活化rH5N8/PR8与MF59辅助剂的剂量,每隔7天内肌肉注射两次.
这一策略诱导了最强的免疫反应,并提供了有效的保护,免受野生型H5N8 AIV挑战.
确定了特定的疫苗接种参数,以最大限度地提高疫苗的疗效.

结论:

优化的无活化rH5N8/PR8疫苗与MF59辅助剂显示出对H5N8禽流感的显著潜力.
这项研究为开发针对特定特征量身定制的流行性潜在流感疫苗菌株提供了有价值的数据.

关键词:

亚型 H5N8 亚型 H5N8 亚型一个辅助的辅助者.禽流感病毒是禽流感病毒的一种病毒.免疫性免疫性免疫性疫苗疫苗疫苗疫苗

更多相关视频

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

相关概念视频

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...